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INTRODUCTION
The inflammatory bowel diseases (IBDs) are a group of inflammatory conditions of the colon and small intestine. IBDs include Crohn's disease (CD) and ulcerative colitis (UC) and are characterized by spontaneous remittances and relapses (1) . The exact cause of IBDs remain unknown. Available evidence suggests that an abnormal immune response against the microorganisms of the intestinal flora is responsible for the diseases in genetically susceptible individuals (2) . Ulcerative colitis is characterized by continuous inflammation of the intestinal lamina propria, starting from the rectum and potentially involving the whole colonic mucosa. At present, its pathogenesis is still unclear, but evidence suggests that the disease occurs in genetically susceptible subjects and is trigged by environmental factors, which lead to an exaggerated and uncontrolled immune response (3) . Cytokines have a crucial role in the pathogenesis of UC, where they control multiple aspects of the inflammatory response. In particular, the imbalance between pro-inflammatory and anti-inflammatory cytokines that occurs in UC impedes the resolution of inflammation and instead leads to disease perpetuation and tissue destruction (4) . Beside monocyte/macrophages, CD4+ helper T lymphocytes are major producers of cytokines and can be classified according to the type of cytokines they produce: Th1 (IFN-γ and TNF-α), Th2 (IL-4, IL-5 and IL-13), Th17 (IL-6 and IL-17) and Tregs (IL-10 and TGF-β) (5).
Crohn's disease, also known as Crohn syndrome and regional enteritis, is a type of inflammatory bowel disease (IBD) that may affect any part of the gastrointestinal tract from mouth to anus (6) . Crohn's disease is caused by a combination of environmental, immune and bacterial factors in genetically susceptible individuals (7) (8) (9) . It results in a chronic inflammatory disorder, in which the immune system attacks the gastrointestinal tract, with possible direction at microbial antigens (8) (9) (10) . While Crohn's is an immune related disease, it does not appear to be an autoimmune disease (in that the immune system is not being triggered by the body itself) (11) . The exact underlying immune problem is not clear; however, it may be an immunodeficient state (10) (11) (12) . About half of the overall risk is related to genetics, with more than 70 genes found to be involved (13, 14) . The first mutation found to be associated with Crohn's was a frameshift in the NOD2 gene (also known as the CARD15 gene) (15), followed by the discovery of point mutations (16) . Certain characteristic features of pathology point towards Crohn's disease including a transmural pattern of inflammation, meaning the inflammation may span the entire depth of the intestinal wall (17) .
Patients with IBDs are at increased risk for colon cancer (18) (19) (20) (21) . Many authors have reported p53 mutations in epithelium adjacent to dysplasia in IBDs (18) (19) (20) (21) . These alterations of p53 underlie the multistep process of oncogenesis (22) . Vascular endothelial growth factor (VEGF) belongs to a family of platelet-derived growth factors and plays an important role in tumour growth and metastasis (23) . Still, the role of VEGF in the modulation of immune responses remains unclear. The tumour suppressor p16INK4a belongs to the INK4 family of cyclin-dependent kinase (CDK) inhibitors (24) . p16INK4a inhibits cell-cycle progression by preventing cyclin D-CDK 4/6 complex formation. p16INK4a inactivation by deletion, point mutation, or promoter methylation occurs frequently in most tumours (25) . In addition to its role in cancer as an inhibitor of cell-cycle progression, p16 plays important role in the modulation of immune response (26) . In response to DNA damage, wild-type p53 upregulates the p21 (WAF1/Cip1) protein, which is a general inhibitor of CDKs and contributes to G1 cell cycle arrest under these circumstances (27) .
Therefore, the aim of this study was to investigate the expression patterns of p16, p53 and VEGF in affected tissue and serum levels of cytokines TNF-α, IFN-γ, IL-4, IL-6, IL-10 and IL-17 in patients with UC and Crohn's disease. We report higher values of pro-inflammatory cytokines in patients with Crohn's disease and positive staining of p16, p53 and VEGF. Expression of p53 is found to be a highly specific marker in differentiation between UC and Crohn's disease.
MATERIAL AND METHODS

Patients
From May 2011 until March 2013, patients were enrolled at the Center for Gastroenterology, Clinical Centre Kragujevac. All immunological measurements were conducted at the Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac. All ethical approvals were obtained, and research was conducted in accordance with the regulations of Good Clinical and Laboratory Practices.
We investigated a total of 24 patients with ulcerative colitis (15 males and 9 females; mean age: 48.38 ± 17.94 years) and 7 patients with Crohn's disease (4 males and 3 females; mean age: 20.75 ± 1.71 years). The diagnoses of ulcerative colitis and Crohn's disease were based on endoscopic and histopathological criteria. The study did not include patients with inflammatory bowel disease who were previously treated with antibiotics, aminosalicylates, corticosteroids, immunosuppressive agents, or biological therapy. All subjects had a complete medical history, including physical examination, routine laboratory tests and diagnostic imaging (chest X-ray, abdominal ultrasound, abdominal computed tomography scan and endoscopy).
Assessment of serum level TNF-α, IL-6, IL-17 and TGF-β
Blood samples were obtained before application of therapy. The control group consisted of 37 healthy male and female blood donors at the Clinical Centre of Kragujevac. The control group was matched with the experimental groups on the basis of gender. Serum was separated, and all serum samples were kept at -20°C before use. Serum levels of cytokines were measured as described before (28), using sensitive enzyme-linked immunosorbent assay (ELI-SA) kits (R&D Systems Minneapolis, MN, USA for IL-6, TNF-α, TGF-β and IL-17), specific for human cytokines, according to the manufacturer's instructions.
Immunohistochemical study of VEGF, p16 and p53
Immunohistochemical staining was performed using the streptavidin-biotin technique, as previously described (29) . Immunohistochemistry was performed on multiple endoscopically obtained colonic mucosal biopsy specimens collected from patients with ulcerative colitis and patients with Crohn's disease. Paraffin-embedded tissue samples were sectioned at 4-5 μm. Briefly, tissue samples were deparaffinised. Antigen retrieval was performed by microwave heating for 20 min in 10 mM sodium citrate buffer (pH 6.0). The sections were incubated with 3% hydrogen peroxide to block endogenous peroxidase activity and then incubated with mouse monoclonal antibodies against VEGF (ab16883, Abcam, Cambridge, UK, at a 1:200 dilution), p53 (ab17869-250, Abcam, Cambridge, UK, at a 1:200 dilution) and p16 (sc-81156, Santa Cruz Biotechnology, Santa Cruz, CA, USA, at a 1:50 dilution) for 60 min in a humidity chamber, followed by incubation with biotinylated secondary antibodies. The ABC (AvidinBioton peroxidase Complex) method was used for detection. The slides were examined by conventional light microscopy. Negative controls were treated identically, but with the primary antibodies omitted. Positive controls consisted of tissue known to contain the protein of interest. The VEGF, p16 and p53 stained sections were assessed semiquantitatively by two pathologists. The staining score was evaluated as the percentage of stained cells out of the total number of evaluated cells. The extent of each staining pattern of p16 and p53 was recorded as the number of positive nuclei per 250 cells. The same pattern was used for VEGF in cytoplasm. Percentage of positive cells was determined by counting 5 non overlapping microscopic fields at 400x magnification. Staining for p16, p53 and VEGF was defined as positive when >10% of the cells were stained and as negative when ≤ 10% of the cells were stained (30, 31) .
Statistical analysis
Software package IBM SPSS Statistics 20 was used for the statistical analysis. Data are grouped and shown in tables and graphs. Methods of descriptive statistics were used in determining measures of central tendency and variability. The results are presented as the mean and standard deviation. Pearson's and Spearman's correlation coefficients were used for determining the strength and direction of correlation between the variables. A chi-squared test was used for determining the independence of variables. In determining statistically significant differences between the means of the two groups, Student's t-test for independent samples was used if the data were normally distributed, while a Mann-Whitney U-test was used for data that were not normally distributed. A One-Way ANOVA test was used for determining statistically relevant differences between the means of various groups of normally distributed data and a Kruskal-Wallis test was used for data that were not normally distributed. In determining the normality of data distribution, a Kolmogorov-Smirnov test and a Shapiro-Wilk test were used. Levene's test for equality of variances was used to determine the homogeneity of variances. This test determines if the results from two groups of data have equal variances. An ROC curve was used for the review of sensitivity and specificity. All statistical analyses in this paper were conducted with a confidence interval of 95%. The results of the statistical analysis were taken as statistically significant if the level of probability of null hypothesis was lower than 5%, that is to say, if the relevance of the test was p<0.05.
RESULTS
Higher frequency of patients with Crohn's disease had positive staining of p16, p53 and VEGF, in comparison to patients with UC
The expression patterns of p16, p53 and VEGF protein were assessed by immunohistochemistry on biopsy specimens. All patients with UC and Crohn's disease were classified on the basis of positive (>10% positive cells) or negative (≤10% positive cells) immunostaining of p16, p53 and VEGF, respectively. Only nuclear staining of p16 and p53 was scored. The frequency of patients with Crohn's disease that had positive staining for p16 and p53 was significantly higher when compared to UC subjects (p=0.024; p=0.041, respectively).
Biopsy specimens of all patients with Crohn's disease were p16 positive, while 83% of specimens from patients with Crohn's disease had positive p53 nuclear staining (Fig  1) . VEGF expression was found to occur in the cytoplasm and cell membrane. Of specimens from patients with Crohn's disease, 82% had positive VEGF staining, with no significant difference between groups (UC vs CD; Fig 1) .
Representative images of immunostaining for the mentioned markers examined in tissue of patients with ulcerative colitis and Crohn's disease are shown in Figure 2 .
Serum concentrations of pro-and anti-infl ammatory mediators and their ratios in UC patients and patients with Crohn's disease
Next, we examined the serum levels of pro-inflammatory (IL-4, IL-6, TNF-α, IFN-γ and IL-17) and anti-inflammatory mediators (IL-10) in patients with ulcerative colitis and Crohn's disease. Twenty-four patients with ulcerative colitis, 15 males and 9 females with a mean age of 48.38 ± 17.94, and seven patients with Crohn's disease, 4 males and 3 females with mean age 20.75 ± 1.71 years, were studied. We obtained a significantly higher serum level of TNF-α (p=0.032; Fig 3A, left panel) and IL-6 (p=0.039; Fig 3A, right panel) in patients with Crohn's disease, in comparison with the UC patients. It had been suggested that the ratio of counterregulatory cytokines could be a marker of disease progression. Therefore, we analysed ratios of pro-and anti-inflammatory cytokines and found a significantly higher value of IL-6/ TGF-β ratio (p=0.045; Fig 3B, left panel) and IL-17/TGF-β ratio (p=0.024; Fig 3B, right panel) in patients with Crohn's disease compared to patients with UC.
Logistic regression analyses of p53 expression and TNF-α serum level in colorectal infl amed tissue
Binary logistic regression showed that higher expression of p53 strongly correlated with the presence of Crohn's disease. Analysis showed that p53 can be a valuable marker for differentiating Crohn's disease from UC (sensitivity 78.6%, specificity 95.2%, cut-off >0; Fig 4, right  panel) . Analysis also showed that TNF-α (sensitivity 78.7%, specificity 87.5%, Fig 5, left panel) can be a valuable marker for distinguishing UC and Crohn's disease. The optimal cut-off value estimated for TNF-α that allows discrimination between UC and Crohn's disease patients was 35 pg/ ml. For this cut-off, we determined sensitivity to be 78.7% and specificity 87.5%.
DISCUSSION
In the present study, we found a predomination of proinflammatory cytokines in patients with Crohn's disease compared to patients with UC. Positive staining of p16, p53 and VEGF was detected in the mucosa of both groups, and its expression was significantly higher in Crohn's disease compared to ulcerative colitis. Furthermore, the expression of p53 and serum values of TNF-α higher than 35 pg/ml present a highly sensitive and specific marker in the differentiation between Crohn's disease and UC.
The type of immune response is different in CD and UC. CD is characterized by granuloma formation, while the hallmark of UC is infiltration of neutrophils with the destruction of the epithelium (32) . Additionally, CD is dominantly followed by a Th1-type immune response (with the production of IL-2, IL-8, IL-12, IFN-γ and TNF-α) (32), while in UC, a Th2 type immune response dominates (production of IL-4, IL-5, IL-6, IL-10 and IL-13), which stimulates humoral immunity (32) . In this study, we estimated significantly higher concentrations of TNF-α and IL-6 in the serum of patients with CD compared to those with UC ( Fig 4A) . The role of TNF-α in the pathogenesis of CD is well known (33) . The high systemic values of TNF-α in patients with CD is in accordance with data from the literature (32) (33) (34) . According to the aforementioned data, it may be assumed that the increased TNF-α in sera induces IL-6 production, with subsequent elevation of IL-6 in the serum of patients with CD. Increased concentrations of IL-6 in patients with CD, in comparison to UC, can also be explained by the fact that all patients had the fistulating form of CD. The fistulised form of CD can cause changes in colon microenvironment, with subsequent changes in the type of immune response (33) .
Furthermore, we analysed ratios of contra-regulatory cytokines IL-6, IL-17 and TGF-β, and documented that patients with CD (compared to patients with UC) had significantly higher IL-6/TGF-β and IL-17/TGF-β ratios ( Fig  4B) . TGF-β is an inhibitory cytokine and the key regulator of immune homeostasis and inflammation (35) . It prevents proliferation of leukocytes and their activation and takes a part in the inhibition and spread of the inflammatory process (35) . Decreased activity of the TGF-β is considered to be responsible for the development of a variety of autoimmune diseases, including inflammatory bowel disease (35) . TGF-β is a negative regulator of inflammation of the bowel mucosa (36) and also an important factor for the development of regulatory T lymphocytes (37) . Regulatory T cells produce a large amount of TGF-β, which plays a significant role in the maintenance of peripheral immune tolerance and immunosuppression (38) . Th17 cells are a sub-population of helper T lymphocytes which have been isolated for the first time from the peripheral blood of patients with CD. As a subclass of lymphocytes, which produce a large amount of IL-17 and IL-23 (39) , it is believed that Th17 cells promote tissue destruction during inflammatory processes and are significant in the genesis and development of chronic inflammatory diseases (40) . TGF-β, in combination with IL-6, directs the differentiation of naive T cells into Th17 cells (36, (40) (41) (42) (43) . Participation of TGF-β in the genesis of Th17 lymphocytes is quite surprising because TGF-β alone has an anti-inflammatory effect and is important for the generation of regulatory T lymphocytes (40) . It has been assumed that there is a natural antagonism be- tween Th17 and regulatory T cells, and in the absence of an inflammatory environment, the TGF-β produced will induce suppression of the effector T cells and the formation of regulatory T cells, which is important for maintenance of immuno-tolerance (37) . In our study, elevated IL-6 in the sera of patients with CD may suppress formation of regulatory T cells and induce the development of a Th17 immune response (37) . Additionally, increased production of pro-inflammatory cytokines, such as TNF-α, reduce the secretion of TGF-β (35) . IL-17 mediates the pathogenesis of CD, and it is a potent inducer of local infiltrations with neutrophils (44) . Additionally, IL-17 induces expression of other pro-inflammatory cytokines (TNF-α, IL-1, IL-6) (45), nuclear growth factor (NF-kB) and the MAPK kinases (46) . IL-17 has an effect on fibroblasts and induces the secretion of metalloproteinases, which further contribute to tissue damage (47) .
We also analysed expression of anti-oncogenes p16 and p53 and VEGF in affected tissue.
The percentage of patients with CD and a positive expression of p16, p53 and VEGF was higher than those with UC (Fig 1) . Vascular proliferation in the submucosa is typical for CD (33) . In this study, all subjects with CD had the highest histological grade of inflamed colonic mucosa (histological grade III), which was not the case with subjects with UC. In inflammatory bowel disease, higher expression of p16 and p53 genes correlates with a higher histological grade of inflamed mucosa (48, 49) . We assume that a higher degree of histological damage of inflamed mucosa correlates with a higher alteration of p16 and p53 genes. Various studies have revealed that wild type p16 and p53 reduce angiogenesis via down regulation of VEGF (50) (51) (52) . We proposed that altered p16 and p53 may induce VEGF overexpression and stimulate angiogenesis (29) . Higher expression of anti-oncogenes p16 and p53 indicates a loss of function and facilitates neovascularization via VEGF. Our results suggest that enhanced systemic pro-inflammatory immune response correlates with local tissue angiogenesis, in patients with CD.
VEGF also has a role in inflammation and immunity, as a key mediator in recruitment of inflammatory cells and enhanced expression of co-stimulatory molecules on recruited and resident mononuclear cells, leading to up-regulation of the pro-inflammatory cytokines Th1 and Th17 (53, 54) .
Finally, we assessed the expression of studied tissue markers and cytokines as useful markers in the assessment of CD. P53 expression showed a high sensitivity and specificity for CD in differentiating from UC (Fig 4) . We also envisioned the possible role of TNF-α as a biomarker in distinguishing CD from UC and showed that increased levels of TNF-α enhanced the likelihood of UC, compared to CRC (Fig 4) .
The results of this study clearly show the predominance of pro-inflammatory types 1 and 17 of immune response in patients with CD compared to those with UC. We believe that altered p16 and p53 induce enhanced VEGF expression that implicates enhanced production of pro-inflammatory TNF-α and IL-6. TNF-α and IL-6 will further facilitate development of Type 1/17 immune response.
